Nuveen LLC Invests $2.64 Million in Liquidia Technologies, Inc. $LQDA

Key Points

• Nuveen LLC has acquired a new stake in Liquidia Technologies, purchasing 179,085 shares valued at approximately $2.64 million, representing about 0.21% of the company.
• Liquidia Technologies reported a 141.5% year-over-year increase in revenue, although it missed earnings expectations with a reported EPS of ($0.49).
• Several institutional investors have recently shifted their positions in Liquidia Technologies, with 64.54% of the stock now held by institutional investors and hedge funds.

Nuveen LLC acquired a new stake in Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 179,085 shares of the company's stock, valued at approximately $2,642,000. Nuveen LLC owned about 0.21% of Liquidia Technologies at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. Whitefort Capital Management LP raised its holdings in Liquidia Technologies by 16.8% in the 4th quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company's stock valued at $23,370,000 after buying an additional 285,220 shares during the last quarter. Vestal Point Capital LP raised its holdings in Liquidia Technologies by 17.3% in the 4th quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company's stock valued at $20,698,000 after buying an additional 260,000 shares during the last quarter. Tang Capital Management LLC raised its holdings in Liquidia Technologies by 37.5% in the 4th quarter. Tang Capital Management LLC now owns 1,100,000 shares of the company's stock valued at $12,936,000 after buying an additional 300,000 shares during the last quarter. Northern Trust Corp raised its holdings in Liquidia Technologies by 19.5% in the 4th quarter. Northern Trust Corp now owns 589,921 shares of the company's stock valued at $6,937,000 after buying an additional 96,381 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in Liquidia Technologies by 1,484.5% in the 4th quarter. Janus Henderson Group PLC now owns 535,552 shares of the company's stock valued at $6,293,000 after buying an additional 501,752 shares during the last quarter. Institutional investors own 64.54% of the company's stock.

Liquidia Technologies Stock Performance

NASDAQ:LQDA traded up $0.22 during trading hours on Friday, hitting $27.68. 2,174,424 shares of the company traded hands, compared to its average volume of 3,065,696. The company has a debt-to-equity ratio of 9.84, a current ratio of 2.49 and a quick ratio of 2.41. The firm's 50-day simple moving average is $18.89 and its 200-day simple moving average is $16.36. Liquidia Technologies, Inc. has a one year low of $8.75 and a one year high of $28.82.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.06). Liquidia Technologies had a negative return on equity of 232.96% and a negative net margin of 732.17%.The business had revenue of $8.84 million for the quarter, compared to the consensus estimate of $3.90 million. The company's revenue for the quarter was up 141.5% on a year-over-year basis. As a group, equities research analysts predict that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

Analyst Ratings Changes

LQDA has been the subject of a number of recent analyst reports. Jefferies Financial Group initiated coverage on shares of Liquidia Technologies in a research report on Friday, August 15th. They set a "buy" rating and a $43.00 target price for the company. HC Wainwright raised their price objective on shares of Liquidia Technologies from $29.00 to $35.00 and gave the stock a "buy" rating in a research report on Wednesday, May 28th. Oppenheimer set a $13.00 price objective on shares of Liquidia Technologies and gave the stock an "underperform" rating in a research report on Monday, May 19th. Wall Street Zen raised shares of Liquidia Technologies from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Needham & Company LLC raised their price objective on shares of Liquidia Technologies from $32.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $32.11.

Insider Buying and Selling

In related news, insider Jason Adair sold 2,576 shares of Liquidia Technologies stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $14.28, for a total value of $36,785.28. Following the completion of the sale, the insider owned 193,634 shares of the company's stock, valued at approximately $2,765,093.52. This trade represents a 1.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Sarah Krepp sold 2,673 shares of Liquidia Technologies stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $14.28, for a total value of $38,170.44. Following the transaction, the insider directly owned 142,499 shares of the company's stock, valued at $2,034,885.72. The trade was a 1.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,277 shares of company stock worth $1,469,392 in the last quarter. 30.10% of the stock is currently owned by company insiders.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).